| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Arteriosclerosis | 50 | 2022 | 134 | 12.320 |
Why?
|
| Stroke | 72 | 2022 | 2161 | 6.510 |
Why?
|
| Stents | 34 | 2020 | 657 | 5.840 |
Why?
|
| Ischemic Attack, Transient | 22 | 2020 | 167 | 3.630 |
Why?
|
| Angioplasty | 17 | 2020 | 118 | 3.520 |
Why?
|
| Aspirin | 26 | 2022 | 295 | 2.630 |
Why?
|
| Constriction, Pathologic | 39 | 2022 | 236 | 2.510 |
Why?
|
| Fibrinolytic Agents | 16 | 2020 | 377 | 2.200 |
Why?
|
| Brain Ischemia | 24 | 2022 | 665 | 2.170 |
Why?
|
| Carotid Stenosis | 14 | 2020 | 163 | 2.110 |
Why?
|
| Platelet Aggregation Inhibitors | 15 | 2022 | 373 | 1.800 |
Why?
|
| Cerebral Arterial Diseases | 6 | 2013 | 28 | 1.790 |
Why?
|
| Secondary Prevention | 11 | 2017 | 291 | 1.440 |
Why?
|
| Vertebrobasilar Insufficiency | 5 | 2015 | 21 | 1.370 |
Why?
|
| Warfarin | 17 | 2014 | 93 | 1.290 |
Why?
|
| Risk Factors | 47 | 2022 | 5719 | 1.270 |
Why?
|
| Endovascular Procedures | 7 | 2017 | 366 | 1.060 |
Why?
|
| Anticoagulants | 13 | 2011 | 356 | 1.020 |
Why?
|
| Humans | 125 | 2022 | 68525 | 1.010 |
Why?
|
| Cerebrovascular Circulation | 9 | 2020 | 296 | 0.950 |
Why?
|
| Cerebrovascular Disorders | 10 | 2009 | 182 | 0.950 |
Why?
|
| Cerebral Arteries | 8 | 2014 | 50 | 0.910 |
Why?
|
| Research Design | 9 | 2020 | 729 | 0.890 |
Why?
|
| Cerebral Angiography | 12 | 2020 | 151 | 0.800 |
Why?
|
| Magnetic Resonance Angiography | 6 | 2020 | 181 | 0.780 |
Why?
|
| Treatment Outcome | 31 | 2020 | 7028 | 0.720 |
Why?
|
| Myocardial Infarction | 5 | 2021 | 807 | 0.710 |
Why?
|
| Intracranial Arterial Diseases | 7 | 2017 | 15 | 0.710 |
Why?
|
| Cerebral Hemorrhage | 6 | 2014 | 198 | 0.700 |
Why?
|
| Arterial Occlusive Diseases | 5 | 2011 | 134 | 0.700 |
Why?
|
| Male | 71 | 2020 | 37281 | 0.690 |
Why?
|
| Risk Reduction Behavior | 8 | 2017 | 174 | 0.690 |
Why?
|
| Female | 67 | 2020 | 38015 | 0.680 |
Why?
|
| Carotid Artery Diseases | 3 | 2014 | 83 | 0.660 |
Why?
|
| Middle Aged | 63 | 2020 | 21119 | 0.640 |
Why?
|
| Risk Assessment | 15 | 2020 | 2004 | 0.630 |
Why?
|
| Aged | 51 | 2020 | 14842 | 0.630 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2020 | 929 | 0.590 |
Why?
|
| Patient Selection | 3 | 2015 | 592 | 0.570 |
Why?
|
| Neurology | 2 | 2014 | 43 | 0.560 |
Why?
|
| Hemorrhage | 3 | 2020 | 328 | 0.560 |
Why?
|
| Recurrence | 15 | 2020 | 948 | 0.540 |
Why?
|
| Arteries | 3 | 2022 | 108 | 0.540 |
Why?
|
| Neurosurgical Procedures | 2 | 2013 | 98 | 0.520 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2017 | 296 | 0.500 |
Why?
|
| Follow-Up Studies | 15 | 2016 | 3256 | 0.500 |
Why?
|
| Middle Cerebral Artery | 4 | 2020 | 57 | 0.490 |
Why?
|
| Vascular Surgical Procedures | 2 | 2013 | 168 | 0.490 |
Why?
|
| Ticlopidine | 6 | 2015 | 118 | 0.480 |
Why?
|
| Mechanical Thrombolysis | 1 | 2014 | 29 | 0.480 |
Why?
|
| Radiology, Interventional | 1 | 2014 | 21 | 0.480 |
Why?
|
| Postoperative Complications | 6 | 2017 | 1615 | 0.480 |
Why?
|
| Carotid Artery, Common | 1 | 2013 | 25 | 0.480 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 848 | 0.470 |
Why?
|
| Awards and Prizes | 1 | 2013 | 27 | 0.460 |
Why?
|
| Time Factors | 15 | 2020 | 4655 | 0.460 |
Why?
|
| Thrombectomy | 2 | 2013 | 238 | 0.460 |
Why?
|
| Blood Pressure | 5 | 2020 | 1447 | 0.450 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 212 | 0.450 |
Why?
|
| United States | 23 | 2020 | 7335 | 0.440 |
Why?
|
| Atherosclerosis | 3 | 2017 | 204 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2020 | 2222 | 0.430 |
Why?
|
| Population Surveillance | 1 | 2014 | 285 | 0.430 |
Why?
|
| Embolism | 2 | 2011 | 45 | 0.420 |
Why?
|
| Neuroimaging | 1 | 2013 | 122 | 0.410 |
Why?
|
| Brain Diseases | 4 | 2005 | 78 | 0.400 |
Why?
|
| Brachial Artery | 1 | 2011 | 34 | 0.400 |
Why?
|
| Cerebral Infarction | 6 | 2021 | 103 | 0.390 |
Why?
|
| Disease Management | 4 | 2020 | 248 | 0.390 |
Why?
|
| Brain Infarction | 3 | 2020 | 54 | 0.390 |
Why?
|
| Coronary Disease | 4 | 2003 | 358 | 0.380 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 503 | 0.350 |
Why?
|
| Vertebral Artery | 4 | 2020 | 22 | 0.330 |
Why?
|
| Drug Therapy, Combination | 4 | 2015 | 648 | 0.320 |
Why?
|
| Angioplasty, Balloon | 3 | 2017 | 110 | 0.320 |
Why?
|
| Exercise | 3 | 2019 | 657 | 0.320 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2008 | 73 | 0.320 |
Why?
|
| Cerebral Revascularization | 1 | 2008 | 45 | 0.310 |
Why?
|
| Carotid Artery, Internal | 2 | 2020 | 85 | 0.310 |
Why?
|
| Endpoint Determination | 5 | 2018 | 82 | 0.300 |
Why?
|
| Thrombolytic Therapy | 1 | 2009 | 233 | 0.300 |
Why?
|
| Prospective Studies | 18 | 2020 | 3702 | 0.290 |
Why?
|
| Brain | 8 | 2017 | 2175 | 0.290 |
Why?
|
| Endarterectomy, Carotid | 3 | 2017 | 110 | 0.280 |
Why?
|
| Lipoproteins, LDL | 2 | 2020 | 343 | 0.280 |
Why?
|
| Basilar Artery | 3 | 2020 | 38 | 0.280 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 4 | 2020 | 99 | 0.270 |
Why?
|
| Cognition | 3 | 2019 | 512 | 0.260 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 82 | 0.240 |
Why?
|
| Cerebral Ventricles | 2 | 2017 | 36 | 0.240 |
Why?
|
| Aphasia | 1 | 2005 | 119 | 0.230 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2017 | 61 | 0.230 |
Why?
|
| Carotid Arteries | 4 | 2020 | 110 | 0.220 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1851 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 536 | 0.210 |
Why?
|
| Double-Blind Method | 8 | 2011 | 1737 | 0.200 |
Why?
|
| Smoking | 3 | 2020 | 1449 | 0.200 |
Why?
|
| Collateral Circulation | 2 | 2011 | 34 | 0.200 |
Why?
|
| Intracranial Embolism | 1 | 2020 | 25 | 0.190 |
Why?
|
| Drug Administration Schedule | 2 | 2020 | 567 | 0.190 |
Why?
|
| Cerebrovascular Trauma | 1 | 2020 | 7 | 0.190 |
Why?
|
| Head Injuries, Closed | 1 | 2020 | 9 | 0.190 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2020 | 20 | 0.190 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2020 | 54 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 4 | 2018 | 329 | 0.190 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 87 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2020 | 91 | 0.180 |
Why?
|
| Prognosis | 10 | 2020 | 2093 | 0.180 |
Why?
|
| Sex Factors | 3 | 2020 | 1265 | 0.180 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 90 | 0.180 |
Why?
|
| Life Style | 2 | 2020 | 338 | 0.180 |
Why?
|
| Adult | 22 | 2020 | 21375 | 0.180 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 1046 | 0.180 |
Why?
|
| Aged, 80 and over | 8 | 2017 | 4843 | 0.170 |
Why?
|
| Vascular Diseases | 3 | 2006 | 94 | 0.170 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2020 | 125 | 0.170 |
Why?
|
| Incidence | 7 | 2013 | 1582 | 0.170 |
Why?
|
| Diagnostic Imaging | 2 | 2012 | 201 | 0.160 |
Why?
|
| Biostatistics | 1 | 2018 | 43 | 0.160 |
Why?
|
| Risk | 7 | 2017 | 563 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 84 | 0.160 |
Why?
|
| Age Factors | 2 | 2020 | 1860 | 0.160 |
Why?
|
| Vasospasm, Intracranial | 1 | 2017 | 16 | 0.160 |
Why?
|
| Astronauts | 1 | 2017 | 20 | 0.150 |
Why?
|
| Weightlessness | 1 | 2017 | 25 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.150 |
Why?
|
| Antihypertensive Agents | 2 | 2011 | 497 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.150 |
Why?
|
| Postprandial Period | 1 | 2017 | 21 | 0.150 |
Why?
|
| Space Flight | 1 | 2017 | 40 | 0.150 |
Why?
|
| Exercise Therapy | 1 | 2019 | 183 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 346 | 0.140 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2016 | 10 | 0.140 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 1465 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 176 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2015 | 237 | 0.130 |
Why?
|
| Cholesterol | 1 | 2016 | 331 | 0.130 |
Why?
|
| Biomarkers | 2 | 2020 | 1593 | 0.130 |
Why?
|
| South Carolina | 2 | 2020 | 2750 | 0.130 |
Why?
|
| Intracranial Pressure | 2 | 2017 | 58 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2017 | 402 | 0.130 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 1991 | 37 | 0.130 |
Why?
|
| Pulmonary Veins | 2 | 1991 | 56 | 0.130 |
Why?
|
| Heart Atria | 3 | 1994 | 206 | 0.120 |
Why?
|
| Comorbidity | 5 | 2016 | 1425 | 0.120 |
Why?
|
| Mitral Valve Stenosis | 1 | 1993 | 15 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2014 | 119 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2016 | 342 | 0.120 |
Why?
|
| Proportional Hazards Models | 6 | 2015 | 791 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2016 | 866 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2014 | 239 | 0.110 |
Why?
|
| Logistic Models | 1 | 2016 | 1419 | 0.110 |
Why?
|
| Perioperative Period | 1 | 2012 | 24 | 0.110 |
Why?
|
| Nervous System Diseases | 2 | 1992 | 142 | 0.110 |
Why?
|
| Stroke, Lacunar | 1 | 2012 | 3 | 0.110 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 951 | 0.110 |
Why?
|
| Pulmonary Artery | 2 | 1991 | 323 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 2077 | 0.110 |
Why?
|
| Hemodynamics | 2 | 2020 | 705 | 0.110 |
Why?
|
| Forecasting | 1 | 2013 | 277 | 0.100 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2014 | 239 | 0.100 |
Why?
|
| Canada | 2 | 2012 | 266 | 0.100 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2007 | 100 | 0.100 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 27 | 0.100 |
Why?
|
| Arteriovenous Fistula | 1 | 1991 | 25 | 0.100 |
Why?
|
| Sample Size | 1 | 2011 | 79 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 772 | 0.100 |
Why?
|
| Neurologic Examination | 2 | 1992 | 107 | 0.100 |
Why?
|
| Stereotaxic Techniques | 1 | 1991 | 35 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 80 | 0.100 |
Why?
|
| Hypertension | 1 | 2020 | 1531 | 0.100 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 82 | 0.100 |
Why?
|
| Prevalence | 6 | 2019 | 1609 | 0.100 |
Why?
|
| Thrombin | 1 | 1991 | 117 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 1993 | 248 | 0.090 |
Why?
|
| Muscular Diseases | 1 | 1990 | 41 | 0.090 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 1990 | 15 | 0.090 |
Why?
|
| Parietal Lobe | 1 | 1990 | 59 | 0.090 |
Why?
|
| Angiography | 1 | 2010 | 194 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2798 | 0.090 |
Why?
|
| Polyneuropathies | 1 | 1989 | 6 | 0.090 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 546 | 0.090 |
Why?
|
| Radiography | 4 | 2010 | 572 | 0.090 |
Why?
|
| Echocardiography | 4 | 1994 | 515 | 0.090 |
Why?
|
| Temporal Lobe | 1 | 1990 | 125 | 0.090 |
Why?
|
| Demyelinating Diseases | 1 | 1989 | 57 | 0.090 |
Why?
|
| Intracranial Thrombosis | 1 | 2009 | 14 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2011 | 333 | 0.090 |
Why?
|
| Cerebral Cortex | 1 | 1992 | 415 | 0.090 |
Why?
|
| Psychotic Disorders | 1 | 1990 | 157 | 0.090 |
Why?
|
| Biopsy | 1 | 1991 | 539 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 121 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2017 | 7264 | 0.080 |
Why?
|
| Registries | 2 | 2009 | 730 | 0.080 |
Why?
|
| Observer Variation | 2 | 2000 | 330 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2008 | 121 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 4 | 2010 | 186 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 1139 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 458 | 0.080 |
Why?
|
| Hydrocephalus | 1 | 1987 | 40 | 0.080 |
Why?
|
| Markov Chains | 2 | 2018 | 133 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2008 | 182 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2008 | 301 | 0.070 |
Why?
|
| Heparin | 1 | 1987 | 205 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 837 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 438 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 1990 | 621 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 955 | 0.070 |
Why?
|
| Syndrome | 1 | 2005 | 255 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 137 | 0.060 |
Why?
|
| American Heart Association | 2 | 2016 | 142 | 0.060 |
Why?
|
| Genetics, Medical | 1 | 1984 | 17 | 0.060 |
Why?
|
| Mortality | 1 | 2005 | 162 | 0.060 |
Why?
|
| Computers | 1 | 1984 | 63 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2006 | 191 | 0.060 |
Why?
|
| Medical Records | 1 | 1984 | 121 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2014 | 172 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2013 | 714 | 0.060 |
Why?
|
| Blood Coagulation Factors | 1 | 2002 | 44 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2022 | 1329 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2011 | 2323 | 0.050 |
Why?
|
| China | 1 | 2022 | 138 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2007 | 880 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2010 | 938 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2002 | 220 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 301 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2016 | 506 | 0.050 |
Why?
|
| Rupture, Spontaneous | 1 | 2020 | 21 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 43 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2011 | 737 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2008 | 2356 | 0.050 |
Why?
|
| Neck | 1 | 2020 | 62 | 0.050 |
Why?
|
| Causality | 2 | 2002 | 81 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2020 | 197 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2011 | 866 | 0.040 |
Why?
|
| Education, Medical | 1 | 2020 | 147 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2017 | 1548 | 0.040 |
Why?
|
| Cerebrum | 1 | 2017 | 20 | 0.040 |
Why?
|
| Survival Rate | 2 | 2013 | 1055 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 696 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2017 | 94 | 0.040 |
Why?
|
| Telephone | 1 | 2017 | 160 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 370 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1997 | 136 | 0.040 |
Why?
|
| Clinical Competence | 2 | 2012 | 657 | 0.040 |
Why?
|
| Aftercare | 1 | 2017 | 114 | 0.030 |
Why?
|
| Exercise Test | 1 | 1997 | 242 | 0.030 |
Why?
|
| Stroke Rehabilitation | 1 | 2020 | 334 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 424 | 0.030 |
Why?
|
| Guinea Pigs | 1 | 1995 | 124 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 150 | 0.030 |
Why?
|
| Counseling | 1 | 2017 | 279 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 507 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 517 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2017 | 601 | 0.030 |
Why?
|
| Acetazolamide | 1 | 1993 | 8 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2013 | 249 | 0.030 |
Why?
|
| Credentialing | 1 | 2012 | 23 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 1753 | 0.030 |
Why?
|
| Gliosis | 1 | 1992 | 51 | 0.030 |
Why?
|
| Perfusion | 1 | 2012 | 131 | 0.030 |
Why?
|
| Brain Damage, Chronic | 1 | 1992 | 25 | 0.030 |
Why?
|
| Neurosurgery | 1 | 2012 | 42 | 0.030 |
Why?
|
| Heart Diseases | 1 | 1994 | 276 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 699 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2014 | 403 | 0.030 |
Why?
|
| Sensation | 1 | 1991 | 49 | 0.030 |
Why?
|
| Family Practice | 1 | 1994 | 312 | 0.030 |
Why?
|
| Movement Disorders | 1 | 1991 | 58 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 57 | 0.020 |
Why?
|
| Hemostasis | 1 | 1991 | 32 | 0.020 |
Why?
|
| Intracranial Embolism and Thrombosis | 1 | 1990 | 5 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 1991 | 87 | 0.020 |
Why?
|
| Arteriovenous Malformations | 1 | 1991 | 34 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1993 | 453 | 0.020 |
Why?
|
| Endarterectomy | 1 | 1990 | 22 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.020 |
Why?
|
| Postoperative Period | 1 | 1990 | 238 | 0.020 |
Why?
|
| Disabled Persons | 1 | 1990 | 94 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 621 | 0.020 |
Why?
|
| Dementia | 1 | 1991 | 158 | 0.020 |
Why?
|
| Leg | 1 | 1990 | 191 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 1054 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 20877 | 0.020 |
Why?
|
| Professional Competence | 1 | 2009 | 100 | 0.020 |
Why?
|
| Models, Neurological | 1 | 1989 | 136 | 0.020 |
Why?
|
| Device Approval | 1 | 2008 | 6 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2008 | 109 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 94 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1992 | 450 | 0.020 |
Why?
|
| Intracranial Aneurysm | 1 | 1989 | 87 | 0.020 |
Why?
|
| Systole | 1 | 2007 | 149 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 281 | 0.020 |
Why?
|
| Diastole | 1 | 2007 | 161 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 1039 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 239 | 0.020 |
Why?
|
| Internship and Residency | 1 | 1990 | 596 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2002 | 207 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 159 | 0.010 |
Why?
|
| Disease Progression | 1 | 2006 | 1037 | 0.010 |
Why?
|
| Software | 1 | 1984 | 418 | 0.010 |
Why?
|
| Adolescent | 1 | 1991 | 8903 | 0.010 |
Why?
|
| Atrial Function, Right | 1 | 1994 | 2 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1994 | 253 | 0.010 |
Why?
|
| Thorax | 1 | 1991 | 49 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 1991 | 79 | 0.010 |
Why?
|
| Esophagus | 1 | 1991 | 303 | 0.010 |
Why?
|